Classification of the kinetics of factor VIII inhibitors in haemophilia A: Plasma dilution studies are more discriminatory than time-course studies

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 861-867

  Ling, M ^a   Duncan, E M ^a   Rodgers, S E ^a   Somogyi, A A ^a   Crabb, G A ^a   Street, A M ^a   Lloyd, J V ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Factor VIII; Haemophilia A; Inhibitors; Kinetics; Mutation

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G;

ADULT; AGED; ANALYTIC METHOD; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DILUTION CURVE; DISEASE SEVERITY; FEMALE; HEMOPHILIA A; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MUTATION; PRIORITY JOURNAL; TIME;

ADULT; AGED; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; MALE; MIDDLE AGED; MUTATION;

EID: 0034791954     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03067.x     Document Type: Article

References (34)

1. Antibodies to factor VIII: Specificity and kinetics of iso- and hetero-antibodies in hemophilia A
2. Molecular genetics of coagulation factor VIII gene and haemophilia A
3. Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study
4. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs
5. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs
6. Factor VIII antibody in a patient with mild haemophilia
7. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting
8. Inactivation of factor VIII coagulant activity by two different types of human antibodies
9. Factor VIII inhibitors
10. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
11. Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo-/auto-antibodies to factor VIII
12. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII
13. Spontaneous inhibitors of fctor VIII: Kinetics of inactivation of human and porcine factor VIII
14. Factor VIII inhibitors in mild and moderate-severity haemophilia A
15. Factor VIII inhibitors in mild and moderate-severity haemophilia A
16. Hemophilia A
17. Factor VIII inhibitors: Structure and function in autoantibody and hemophilia A patients
18. Immunochemical characterization of factor VIII inhibitors
19. Measurement of factor VIII inhibitors
20. Proceedings: A more uniform measurement of factor VIII inhibitors
21. Characterization of factor VIII B-cell inhibitory epitopes
22. Factor VIII clotting activity
23. Acquired haemophilia A in women post-partum: Management of bleeding episodes and natural history of the factor VIII inhibitor
24. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
25. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
26. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild haemophilia A
27. Autoimmune factor VIII inhibitors
28. The treatment of patients who have factor-VIII antibodies
29. Inhibitors to clotting factors
30. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin
31. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies
32. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization
33. The genetic basis of inhibitor development in haemophilia A
34. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: Improved specificity and reliability